Pneumococcal conjugate vaccine (PCV13) is recommended differently depending on the patient population. In patients six weeks old through 6 years of age, PCV13 is recommended for active immunization for the prevention of diseases considered invasive and caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. It is also recommended for the prevention and active immunization of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. In patients aged 7 to 17 years old, it is recommended for the prevention of invasive disease in subtypes mentioned above. In patients 18 years old and older, it is indicated for active immunization and prevention of pneumococcal pneumonia, caused by the subtypes of S. pneumoniae, as listed above.
Another pneumococcal vaccine, PPSV23, is indicated in the United States for all adults 65 years of age and older, as well as younger patients with conditions that increase the risk for developing pneumococcal pneumonia or invasive pneumococcal disease. Conditions which would indicate PPSV23 in patients younger than 65 years of age are as follows: chronic heart disease excluding hypertension, chronic lung disease including asthma, diabetes mellitus, cerebrospinal fluid leak, cochlear implant, alcohol use disorder, chronic liver disease, cigarette smoking, hemoglobinopathy (including sickle cell disease), congenital/acquired asplenia, congenital/acquired immunodeficiency, human immunodeficiency virus infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, patients receiving immunosuppressive medications (anti-tumor necrosis factor [TNF], chemotherapy agents), solid organ transplant, and multiple myeloma. Recommendations are that all patients who received PPSV23 before the age of 65 years be revaccinated at age 65 unless the vaccine is given less than ten years before the patient turns 65 years old, in which case patients should be revaccinated ten years following the first dose. Recommendations are that patients with functional or anatomic asplenia or immunocompromised individuals receive repeat doses of the vaccination every ten years after the first dose.
PCV13 and PPSV23 Together
While both vaccine types are proven to stimulate long-lasting antibodies in immunocompromised adults, conjugate vaccines have proven to provide some additional benefits. Benefits of polysaccharide conjugate vaccine over traditional polysaccharide vaccine include that conjugate vaccines stimulate the production of these antibodies in infants and toddlers, as opposed to only healthy adults, as seen with polysaccharide vaccines. Conjugate vaccines have also demonstrated to stimulate mucosal immunity, which decreases colonization, as well as proving to provide herd immunity and prime the patient immunologically, for an enhanced host response, unlike traditionally polysaccharide vaccines.
The ACIP recommends that patients receive both vaccinations with any of the following: Cerebrospinal fluid leak, cochlear implant, anatomic/functional asplenia, and immunocompromising conditions listed above.
Both vaccines promote active immunization against the serotypes of the conjugate and capsular polysaccharides contained in the formulation of the vaccine. Immunity develops approximately 2 to 3 weeks after vaccination and lasts for five years. In children and the elderly, re-immunization may be necessary sooner.
PCV 13 actively immunizes against invasive disease caused by S. pneumoniae capsular serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. All of the serotypes are individually conjugated to a CRM197 protein.
PPSV 23 contains 23 capsular polysaccharides types of S. pneumoniae that represent at least 85% to 90% of pneumococcal disease isolates in the United States. It has shown a 50% to 80% efficacy in preventing invasive pneumococcal disease in adults.
S. pneumoniae serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
Single 0.5 ml injection, intramuscularly only. In patients six weeks through 5 years of age, it is administered as part of a 4-dose immunization series, administered as 0.5 mg intramuscular injections given at 2, 4, 6, and 12 to 15 months of age. In all patients six years of age and older, it is administered at a single 0.5 ml intramuscular injection.
Single 0.5 ml injection, intramuscular/subcutaneously
PCV13 and PPSV23 Together
Patients of any age for whom it is recommended receive both vaccinations and should receive them as follows:
If the patient has had no prior vaccination with either vaccine, the patient should receive a single dose of PCV13. Eight weeks or more following this dose, PPSV23 should be given. PPSV23 should be given no sooner than eight weeks following administration of PVC13.
If the patient has received PPSV23 in the past, a single dose of PCV13 should be given one year after the administration of PPSV23. PVC13 should be given no sooner than one year following the administration of PPSV23.
There are reports of the following adverse effects in different age groups. The list includes the most common side effects. However, it is not limited to all of the side effects.
Infants and Toddlers (most commonly reported reactions greater than 5%)
Children Aged 5 to 17 Years Old
Adults 18 Years and Older
Common Reactions to PPSV23 (greater than 10% of patients)
Concomitant administration of PPSV23 and live zoster vaccine showed a reduced immune response to live zoster vaccine. The recommendation that administrations be at least four weeks apart.
Studies done on animals have not shown fetal adverse effects or increased risk to the fetus. It is unknown if the vaccine is excreted with breast milk. Caution is necessary when administering this vaccine to breastfeeding women.
Animal reproduction studies have not been conducted. However, PPSV 23 is an inactivated vaccine, and studies of other inactivated vaccines have not shown to cause increased risk to the fetus. It is unknown if the vaccine is excreted with breast milk. Clinicians should exercise caution when administering this vaccine to breastfeeding women.
PCV13 and PPSV23 contraindications include severe allergic or anaphylactic reaction to any component of the formulation of the vaccine or any diphtheria toxoid-containing vaccine. Pregnancy is not a contraindication to vaccination. Recommendations are that pregnant women at high risk of infection should receive the vaccination.
For the first 15 minutes after administration, patients require monitoring for an allergic reaction like anaphylaxis and syncope.
There is no overdose risk with the administration of the vaccine.
The pneumococcal vaccine is effective and can help reduce the risk of infection. The primary care provider, nurse practitioner, pharmacist, and other healthcare workers should educate patients on the benefits of the pneumococcal vaccine. Over the years, the vaccine has proven to be safe and effective.
|||Marijam A,Olbrecht J,Ozakay A,Eken V,Meszaros K, Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children. Value in health regional issues. 2019 Feb 15; [PubMed PMID: 30776766]|
|||Huang J,Luo S,Huang M,Zhang T,Min Z,Liu C,Zhang Q,Yang J,Min X, Protection against fatal pneumonia through mucosal and subcutaneous immunization with the pneumococcal SP0148 protein. Microbial pathogenesis. 2019 Feb 14; [PubMed PMID: 30772476]|
|||Wiese AD,Griffin MR,Grijalva CG, Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert review of vaccines. 2019 Feb 13; [PubMed PMID: 30759352]|
|||Ozlu T,Bulbul Y,Aydin D,Tatar D,Kuyucu T,Erboy F,Koseoglu HI,Anar C,Sunnetcioglu A,Gulhan PY,Sahin U,Ekici A,Duru S,Ulasli SS,Kurtipek E,Gunay S, Immunization status in chronic obstructive pulmonary disease: A multicenter study from Turkey. Annals of thoracic medicine. 2019 Jan-Mar; [PubMed PMID: 30745939]|
|||Lewnard JA,Hanage WP, Making sense of differences in pneumococcal serotype replacement. The Lancet. Infectious diseases. 2019 Jan 29; [PubMed PMID: 30709666]|
|||Papadatou I,Tzovara I,Licciardi PV, The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects. Vaccines. 2019 Jan 29; [PubMed PMID: 30700048]|
|||Vadlamudi NK,Parhar K,Altre Malana KL,Kang A,Marra F, Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. Vaccine. 2019 Feb 14; [PubMed PMID: 30685252]|
|||Kuronuma K,Takahashi H, Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases. Human vaccines [PubMed PMID: 30698500]|
|||Zhou X,de Luise C,Gaffney M,Burt CW,Scott DA,Gatto N,Center KJ, National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States. International journal of pediatric otorhinolaryngology. 2019 Jan 19; [PubMed PMID: 30690309]|